Edgewood Oncology
PrivateLast Round
Series A
Mar 25, 2024
Total Funding Raised
$20M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Edgewood Oncology operates in Healthcare & Life Sciences and is based in Brookline, Massachusetts. Its latest recorded funding round was a Series A round in March 2024.
Edgewood Oncology is a biotechnology company developing BTX-A51, a small molecule, multi-kinase inhibitor for patients with hematologic malignancies and genetically-defined solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Edgewood Oncology Comparables
Compare Edgewood Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kirilys Therapeutics | 85% | |
| CasInvent Pharma | 75% | |
| Prelude Therapeutics | 73% |
For institutional investors. Book with your work email.
Edgewood Oncology Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Edgewood Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alta Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 41% MoM, from 1.1K to 1.5K.
- Jun 21, 2026
Monthly visitors grew 68% MoM.
For institutional investors. Book with your work email.
Edgewood Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Edgewood Oncology's valuation, stock price, and market status.
Is Edgewood Oncology a public or private company?
Edgewood Oncology is a private company.
What is the current stock price of Edgewood Oncology?
Edgewood Oncology is a private company, so its shares have no public market price. Caplight tracks Edgewood Oncology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Edgewood Oncology worth (valuation)?
Valuation information for Edgewood Oncology is not publicly available.
Can I buy Edgewood Oncology stock?
Edgewood Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Edgewood Oncology's last funding round?
Edgewood Oncology's most recent funding round was Series A on March 25, 2024.
Who are the main investors in Edgewood Oncology?
Key investors in Edgewood Oncology include Alta Partners.
Will Edgewood Oncology IPO soon?
No public IPO plans have been announced for Edgewood Oncology.
How can I track Edgewood Oncology secondary market activity?
Caplight tracks bids, offers, and trades in Edgewood Oncology's shares on secondary markets.